Market News & Trends
FSD Pharma Enters License Agreement to Develop FDA-Approved Veterinary Drugs
FSD Pharma recently announced it has entered into a license agreement with Innovet Italia S.R.L., under which Innovet granted the company a license to use…
AC Immune Announces New Clinical Results in Down Syndrome, Plans for Future Development of Anti-Amyloid-Beta Vaccine
AC Immune SA recently announced plans to advance its novel anti-amyloid-beta (Abeta) vaccine into mid-stage clinical testing to treat and prevent the progression of Down…
Mateon Provides Update on Global Covid-19 Study
Mateon Therapeutics, Inc. recently announced it has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients, which allows for the continuing…
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study
AIM ImmunoTech Inc. recently announced it has dosed the first healthy subjects in its Phase 1 clinical study on the safety of AIM’s drug Ampligen…
Ocuphire Announces Publication of MIRA-1 Phase 2b Results Demonstrating Reduction of Pharmacologically Induced Mydriasis
Ocuphire Pharma recently announced that the results from the MIRA-1 (NCT04024891) Phase 2b clinical trial evaluating the safety and efficacy of Nyxol in the reversal…
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial
Aravive, Inc. recently announced it has dosed its first patient in an open label Phase 1b/2 clinical trial to evaluate the safety, pharmacokinetic, and preliminary…
twoXAR Pharmaceuticals Presents Preclinical Data Showing Significant Efficacy & Safety of Two Novel Chronic Kidney Disease Treatment Candidates
twoXAR Pharmaceuticals recently announced two novel leads for the potential treatment of chronic kidney disease (CKD), TXR-1208 and TXR-1210, demonstrated significant efficacy and excellent tolerability…
Codex DNA Releases World’s First Synthetic Genomes for Emerging SARS-CoV-2 Variants
Codex DNA, Inc., recently announced the release of the world’s first full-length synthetic genomes for two emerging variants of the SARS-CoV-2 virus. The new genomes…
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology
Qualigen Therapeutics, Inc. recently announced it has entered into a Material Evaluation and Option Agreement with the University College London (UCL) to advance development of…
Enzo Announces its Molecular Test Detects Current COVID-19 Variants
Enzo Biochem, Inc. recently announced results of an analysis showing that tests processed on the company’s proprietary GENFLEX molecular diagnostic platform are successfully able to…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….